Effect of mirikizumab on clinical and endoscopic outcomes after 1 anti-TNF failure in patients with moderately to severely active Ulcerative Colitis

被引：0
|
作者：
Hart, A. [1 ,2 ]
Martin-Arranz, M. D. [3 ]
Laharie, D. [4 ]
Matsuoka, K. [5 ]
Dhesi, E. [6 ]
Redondo, I. [6 ]
Baygani, S. [6 ]
Zaremba-Pechmann, L. [7 ]
Samaan, K. [6 ]
Navabi, S. [8 ]
机构：
[1] St Marks Hosp, London, England
[2] Imperial Coll, Dept Metab Digest & Reprod, London, England
[3] Hosp La Paz Inst Hlth Res, Dept Gastroenterol, Madrid, Spain
[4] Univ Bordeaux, Ctr Hosp Univ Bordeaux, Hop Haut Leveque, Bordeaux, France
[5] Toho Univ, Div Gastroenterol & Hepatol, Sakura Med Ctr, Dept Internal Med, Sakura, Japan
[6] Eli Lilly & Co, Indianapolis, IN 46285 USA
[7] HaaPACS GmBH, Stat, Schriesheim, Germany
[8] United Med Doctors, Gastroenterol Hepatol & Obes Med, Long Beach, CA USA
来源：
JOURNAL OF CROHNS & COLITIS | 2024年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
OP14
引用
收藏
页码：I27 / I28
页数：2
相关论文
共 50 条
  • [21] HISTOLOGIC REMISSION AND MUCOSAL HEALING IN A PHASE 2 STUDY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
    Pai, Rish
    Canavan, James
    Tuttle, Jay
    Durante, Michael
    Arora, Vipin
    Milch, Catherine
    Harpaz, Noam
    D'Haens, Geert R.
    Sands, Bruce E.
    Sandborn, William J.
    GASTROENTEROLOGY, 2020, 158 (06) : S1187 - S1187
  • [22] Mirikizumab Pharmacokinetics in Patients with Moderately to Severely Active Ulcerative Colitis: Results from Phase III LUCENT Studies
    Laiyi Chua
    Stuart Friedrich
    Xin Cindy Zhang
    Clinical Pharmacokinetics, 2023, 62 (10) : 1479 - 1491
  • [23] Early Changes in Serum Albumin Predict Clinical and Endoscopic Outcomes in Patients With Ulcerative Colitis Starting Anti-TNF Treatment
    Lee, Sun-Ho
    Walshe, Margaret
    Oh, Eun Hye
    Hwang, Sung Wook
    Park, Sang Hyoung
    Yang, Dong-Hoon
    Byeon, Jeong-Sik
    Myung, Seung-Jae
    Yang, Suk-Kyun
    Greener, Tomer
    Weizman, Adam, V
    Silverberg, Mark S.
    Ye, Byong Duk
    INFLAMMATORY BOWEL DISEASES, 2021, 27 (09) : 1452 - 1461
  • [24] Cost Per Clinical Outcomes With Biologics for the Treatment of Moderately to Severely Active Ulcerative Colitis
    Jansen, Jeroen P.
    Mody, Reema
    Patel, Haridarshan
    Lorenzi, Maria
    Ursan, Iulia
    Alberton, Mark
    GASTROENTEROLOGY, 2015, 148 (04) : S1 - S2
  • [25] Cost per clinical outcomes with biologics for the treatment of moderately to severely active ulcerative colitis
    Jansen, J.
    Mody, R.
    Ursan, I.
    Lorenzi, M.
    Patel, H.
    Alberton, M.
    JOURNAL OF CROHNS & COLITIS, 2015, 9 : S239 - S240
  • [26] MIRIKIZUMAB REGULATES GENES INVOLVED IN ANTI-TNF RESISTANCE AND ULCERATIVE COLITIS DISEASE ACTIVITY
    Steere, Boyd
    Schmitz, Jochen
    Powell, Nicholas
    Higgs, Richard
    Gottlieb, Klaus
    Liu, Yushi
    Jia, Bochao
    Tuttle, Jay
    Sandborn, William J.
    Sands, Bruce E.
    Krishnan, Venkatesh
    GASTROENTEROLOGY, 2020, 158 (06) : S1189 - S1189
  • [27] Mirikizumab regulates genes involved in anti-TNF resistance and ulcerative colitis disease activity
    Steere, B.
    Schmitz, J.
    Powell, N.
    Higgs, R.
    Gottlieb, K.
    Jia, Y. Liu B.
    Tuttle, J. L.
    Sandborn, W. J.
    Sands, B. E.
    Krishnan, V.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S103 - S104
  • [28] Extended induction treatment with mirikizumab in patients with moderately to severely active ulcerative colitis: results from a Phase 2 trial
    Sandborn, W. J.
    Ferrante, M.
    Bhandari, B. R.
    Berliba, E.
    Hibi, T.
    D'Haens, G. Geert R.
    Tuttle, J.
    Krueger, K.
    Friedrich, S.
    Durante, M.
    Arora, V.
    Feagan, B.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 : S54 - S54
  • [29] REDUCTION IN INFLAMMATORY BIOMARKERS IN A PHASE 2 STUDY OF MIRIKIZUMAB IN THE TREATMENT OF PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS
    Sandborn, William J.
    Sands, Bruce E.
    Kobayashi, Taku
    Tuttle, Jay
    Schmitz, Jochen
    Durante, Michael
    Higgs, Richard E.
    Canavan, James
    Siegel, Robert
    Ferrante, Marc
    GASTROENTEROLOGY, 2019, 156 (06) : S1094 - S1095
  • [30] EXTENDED TREATMENT WITH MIRIKIZUMAB IN PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM A PHASE 2 TRIAL
    Sandborn, William J.
    Ferrante, Marc
    Bhandari, Bal R.
    Berliba, Elina
    Hibi, Toshifumi
    D'Haens, Geert R.
    Tuttle, Jay
    Krueger, Kathryn A.
    Friedrich, Stuart
    Durante, Michael
    Arora, Vipin
    Feagan, Brian G.
    GASTROENTEROLOGY, 2019, 156 (06) : S1094 - S1094
12345